title: Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review.
abstract: Vitamin D deficiency is very prevalent in dialysis and peritoneal dialysis (PD) patients show lower levels of cholecalciferol (25(OH)D3) than hemodialysis patients. We conducted a systematic narrative review to assess the effects of vitamin D therapy on control of secondary hyperparathyroidism and clinical outcomes induced by vitamin D pleiotropic effects. Medline database was searched for cohort and intervention studies reporting data on vitamin D (all sterols including synthetic analogs) and peritoneal dialysis without language restriction. Two authors independently extracted data. Twenty-nine observational and eleven interventional studies were identified for inclusion (1,036 subjects). PTH levels decreased in twenty-nine studies, increased in one study and remained stable in ten studies. Thirty-three studies analyzed the oral route for vitamin D administration, ten the intraperitoneal, one the subcutaneous and one the intravenous. A significant decrease of peritonitis risk was observed in two studies. Proteinuria decreased in four studies and remained stable in one study. Peritoneal protein loss decreased in one study and was stable in two studies. Studies on the therapeutic effects of vitamin D in PD are limited and describe small population samples. Moreover, vitamin D compounds do not consistently reduce PTH levels. The administration of active vitamin D in PD may have interesting pleiotropic effects such as decreasing proteinuria and peritoneal protein loss. According to these effects, vitamin D could help to preserve residual renal function and ensure efficient peritoneal membrane dialysance.
authors.affiliation: Division of Nephrology, Dialysis and Transplantation, Azienda Ospedaliero Universitaria Consorziale, Policlinico di Bari, Piazza G. Cesare, 11, 70124, Bari, Italy, roberto.russo@policlinico.ba.it.
authors.forename: Roberto
authors.initials: R
authors.lastname: Russo
authors.forename: Marinella
authors.initials: M
authors.lastname: Ruospo
authors.forename: Mario
authors.initials: M
authors.lastname: Cozzolino
authors.forename: Luca
authors.initials: L
authors.lastname: De Nicola
authors.forename: Andrea
authors.initials: A
authors.lastname: Icardi
authors.forename: Ernesto
authors.initials: E
authors.lastname: Paoletti
authors.forename: Sandro
authors.initials: S
authors.lastname: Mazzaferro
mesh_terms: D015415:Biomarkers / Q000097:blood; D002112:Calcifediol / Q000097:blood; D019587:Dietary Supplements / Q000009:adverse effects; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D010281:Parathyroid Hormone / Q000097:blood*; D010530:Peritoneal Dialysis / Q000009:adverse effects; D011507:Proteinuria / Q000453:epidemiology; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D015415:Biomarkers; C470125:PTH protein, human; D010281:Parathyroid Hormone; D014807:Vitamin D; D002112:Calcifediol